Psyence Biomedical shares rise 22.4% after-hours on equity investment deal acquiring 2,900 shares from Psyence Labs.

Psyence Biomedical surged 22.4% in after-hours trading following an equity investment and stake acquisition deal with Psyence Labs. The company agreed to acquire 2,900 shares of Psyence Labs at $1,724 per share, totaling $5 million, while Psyence Labs gained a 49.98% stake in Psyence Biomedical through a share issuance. The transaction followed the exercise of a previously disclosed put option, signaling strategic alignment and confidence in the company’s value. The significant investment and increased ownership by Psyence Labs suggest a strengthening of ties between the entities, potentially unlocking synergies and boosting investor sentiment. This move aligns with the stock’s sharp after-hours rally, driven by the perceived value of the partnership and its implications for future growth.